Severe Interstitial Lung Disease Associated with Amrubicin Treatment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Severe Interstitial Lung Disease Associated with Amrubicin Treatment

Published:2010-09 Issue:9 Volume:5 Page:1435-1438
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Yoh Kiyotaka,Kenmotsu Hirotsugu,Yamaguchi Yoko,Kubota Kaoru,Ohmatsu Hironobu,Goto Koichi,Niho Seiji,Ohe Yuichiro,Saijo Nagahiro,Nishiwaki Yutaka

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference19 articles.

1. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex;Hanada;Jpn J Cancer Res,1998

2. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells;Yamaoka;Jpn J Cancer Res,1998

3. Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: Comparative study with doxorubicin;Suzuki;Invest New Drugs,1997

4. Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs;Noda;Invest New Drugs,1998

5. Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts;Morisada;Jpn J Cancer Res,1989

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anticancer Drugs (TS-1, Taxanes, CPT-11, Platinum-Containing Drugs, Etc.);Analysis File of Drug-Induced Lung Injury;2024

2. Lung cancer;Cardio-Oncology Practice Manual : a Companion to Braunwald 's Heart Disease;2023

3. Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients;Translational Lung Cancer Research;2022-09

4. Carboplatin plus nab‐paclitaxel for recurrent small cell lung cancer: A phase II study;Thoracic Cancer;2022-03-22

5. Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors;Chest;2021-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3